3737 Market Street
About Spark Therapeutics
Spark Therapeutics is developing curative, one-time gene therapy products with the potential to transform the lives of patients and re-imagine the treatment of debilitating diseases. Spark's lead gene therapy candidate, for RPE65-related blindness, is currently in Phase 3 clinical trials with the potential to be the first approved gene therapy in the United States, and the first approved treatment to address the significant unmet needs of patients living with blindness due to inherited retinal dystrophies.
Additionally, the company has clinical and preclinical programs in other inherited retinal dystrophies and hematological disorders, and a proprietary manufacturing platform that has successfully supported human gene therapy trials across diverse therapeutic areas and routes of administration. Spark’s founding team includes scientists who led the movement to develop gene therapy as a new treatment paradigm, establishing clinical proof of concept in the eye and liver and contributing key insights to the field that have resulted in a resurgence of industry interest in gene-based medicines.
Spark is based in Philadelphia, PA and was spun out of The Children's Hospital of Philadelphia in October 2013. In May 2014, Spark announced the completion of a $72.8 million Series B financing led by Sofinnova Ventures, bringing the company's total funding raised to $82.8 million to-date. To learn more about Spark visit www.sparktx.com.
Founders: Jeffrey Marrazzo, J. Fraser Wright and Katherine High
CEO: Jeffrey Marrazzo
CTO: J. Fraser Wright
CSO (Scientific): Katherine High
Please click here for Spark Therapeutics job opportunities.
Please click here for clinical trial information.
FOLLOW SPARKS THERAPEUTICS:
Tweets by Sparks Therapeutics
138 articles with Spark Therapeutics
11/20/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Spark Therapeutics Expands Visionary Leadership with Appointment of Michael Retterath as Chief Strategy Officer
Spark Therapeutics, a member of the Roche Group and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced the appointment of Michael Retterath as chief strategy officer.
Dyno will be responsible for the design of the novel AAV capsids that are expected to have improved functional properties for gene therapy. Roche and its subsidiary Spark Therapeutics will take the capsids and conduct preclinical studies with hopes of taking them into the clinic, and eventually t...
10/2/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Spark Therapeutics Deepens Drug Development Expertise in Hematology and Rare Disease with Appointment of Gallia G. Levy, M.D., Ph.D., as Chief Medical Officer
Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced the appointment of Gallia Levy, M.D., Ph.D., as chief medical officer. Dr. Levy will be responsible for strategic and operational leadership across all functions in the product development lifecycle, including setting the global developme
Spark Therapeutics Recognized for Fourth-straight Year as One of Philadelphia’s “Best Places to Work” by the Philadelphia Business Journal
Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that it has been named one of Philadelphia’s “Best Places to Work” for the fourth year in a row by the Philadelphia Business Journal. “In seven years, we have grown to a team of more than 500 employees, who are truly what make Spark T
Spark Therapeutics Announces Updated Data on SPK-8011 from Phase 1/2 Clinical Trial in Hemophilia A at ISTH 2020 Virtual Congress
All five participants in the 5x1011 vg/kg and 1×1012 vg/kg dose cohorts and seven participants in the 2×1012 vg/kg dose show an acceptable safety profile, stable and durable factor VIII expression and substantial improvement in annualized bleed rate (ABR) after between two and 3.3 years follow-up
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Study Demonstrating Role of IdeS in Enabling of Gene Therapy in the Presence of Neutralizing Anti-AAV Antibodies Published in Nature Medicine
Spark Therapeutics, a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced the publication of new research in the journal Nature Medicine demonstrating that treatment with immunoglobulin G-degrading (IgG) enzyme of Streptococcus pyogenes
After four years with the gene therapy company, Chief Medical Officer Kathleen Reape will resign her position.
Katherine High, the longtime head of research and development at Spark Therapeutics, is stepping down from the company as it prepares to be absorbed by Swiss pharma giant Roche.
Consulting firm EY released its annual report on mergers and acquisitions (M&A) to coincide with the JP Morgan Healthcare conference this week. For 2019, EY indicates there were $357 billion in life science deals, an “all-time record,” surpassing the previous high in 2014.
1/10/2020The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019.
12/17/2019The companies had to undergo a number of delays as regulatory agencies from across the globe looked closely at the deal to see if there was a potential the combined companies could create a monopoly in the market and stifle competition.
This marks the eighth such extension for the deal.
Spark Therapeutics Wins Prix Galien USA Award for LUXTURNA® (voretigene neparvovec-rzyl) as Best Biotechnology Product
Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that the Galien Foundation has awarded the prestigious 2019 Prix Galien USA Award for Best Biotechnology Product to LUXTURNA® (voretigene neparvovec-rzyl).
On Thursday, FTC staff reviewing Roche’s $4.8 billion bid for Spark gave the deal a thumbs up after reviewing the potential merger.
This week, Roche said it extended its tender-offer period for outstanding shares of Spark to Oct. 1 from Sept. 3.
Roche and Spark initially agreed to the acquisition in February of this year. The deal has had mutiple delays due to regulatory scrutiny.
As fireworks illuminate the night skies across the United States this weekend in celebration of Independence Day, BioSpace takes a look at some of the highlights of the pharma industry from the first half of 2019 and earlier that provides millions of patients with the independence of health.